ZNF334 Knockout cell line (EA.hy 926) – Genotype Verified & Ready-to-use

Red cotton OmniCell bank

10000⁺

Gene Knockout Cell Lines

2000⁺

Luc/EGFP/Cas9 Tool Cell Lines

1000⁺

Wild-type Cell Lines

ZNF334 Knockout cell line (EA.hy 926)

Copy Product Info

Catalog#

YKO-HA204894

Species

Human

Target Cell Line

EA.hy 926

Size

1*10^6

Gene

ZNF334

Storage conditions

Shipped on dry ice; Store in liquid nitrogen

Overview

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZNF345 (zinc finger protein 345) encodes a protein with sequence-specific double-stranded DNA-binding activity. It is predicted to function as an RNA polymerase II-specific transcriptional regulator and to participate in regulation of transcription. ZNF345 is predicted to act in the nucleus, consistent with a role in controlling gene expression through interactions with specific DNA regulatory sequences.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

KO Cell Construction Strategy

Adopting Red Cotton CRISPR Gene Editing Designer (www.rc-crispr.com), two sgRNAs targeting the ZNF334 gene are designed to generate a knockout strategy. The two sgRNA sequences are subsequently cloned into the EZ-editor™ vector and introduced into EA.hy 926 cells via electroporation or lentiviral transduction. Single-cell clones are then generated using the limiting dilution method. Genomic DNA from individual clones is subjected to nucleic acid lysis and PCR amplification using the EZ-editor™ Monoclone Genotype Validation Kit (Cat# YK-MV-1000). The edited loci are further verified by Sanger sequencing to confirm the genotype. After secondary validation and quality confirmation, ZNF334 Knockout cell line (EA.hy 926) is expanded and cryopreserved for downstream applications.

Product Overview

ZNF334 Knockout cell line (EA.hy 926)

The ZNF334 Knockout cell line (EA.hy 926) is generated by targeted disruption of the ZNF334 gene in EA.hy 926 cells. This cell line is designed to investigate the role of ZNF334 in cellular function and gene regulation, as well as its potential involvement in disease-related pathways.

KO Cell Line

ZNF334 Knockout cell line (EA.hy 926)

Gene ID

55713

Catalog

YKO-HA204894

Gene Name

ZNF334

Product Category

Knockout(KO) Cell Line

Gene Information

NCBI

Species

Human

Mycoplasma test

Negative

Cell Morphology

Endothelial cells, adherent

Catalog Status

-

Culture method

90%DMEM+10%FBS

Shipping

Cryopreserved Cells shipped in dry ice

Passage ratio

1:2~1:3

Storage Condition

Liquid nitrogen

Quality Control

All KO cell products are tested and confirmed to be free of bacterial, viral, mycoplasma contamination, and other adventitious agents.

Applications

For research use only. Not intended for use in diagnostic, therapeutic, clinical, or other applications.

Key Advantages

Easy to use

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations

High-efficient KO

These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.

Curated cells

Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Quality Control Specifications

1. Bacteria and Fungi Test

None Detected.

2. Mycoplasma test

Negative.

3. Knockout Strategy

Targeted knockout region: EExon 5

Reference Transcript: NM_018102

Frameshift Mutation Strategy

4. STR Authentication

Download STR Report

Intended use

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use

References

More

FAQ

Q1. How to Contact Support if Issues Arise After Receiving the KO Cells?

If any abnormalities are observed after receiving the cells, please provide the following information based on the stage of use and contact us promptly for assistance:

(1) Issues upon delivery: Please provide photos of the cells at the time of receipt along with a brief description of the issue. We will offer after-sales support accordingly.

(2) Issues after thawing or passaging: Please provide microscopic images of the cells before and after thawing/passaging, along with a detailed description of the experimental procedures. Our technical team will provide professional support.

Q2. What Information Is Required When Reporting KO Cell Product Issues?

Q3. How Should the KO cell Product Be Stored Upon Receipt?

Q4. Shipping Method

Q5. Are the Knockout Cell Lines Stable for Passaging? Is Authentication Provided?